CytomX Therapeutics, Inc. Stock-Based Compensation
CytomX Therapeutics, Inc. (CTMX) reported Stock-Based Compensation of $7.28 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-06
- CytomX Therapeutics, Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $2.58M, a 80.08% increase year-over-year.
- CytomX Therapeutics, Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $4.71M, a 134.36% increase year-over-year.
- CytomX Therapeutics, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $1.48M, a 21.50% decline year-over-year.
- CytomX Therapeutics, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $1.38M, a 30.63% decline year-over-year.
- CytomX Therapeutics, Inc. share-based payment arrangement, noncash expense for fiscal 2025 was $6.30M, a 17.81% decline from fiscal 2024.
- CytomX Therapeutics, Inc. share-based payment arrangement, noncash expense for fiscal 2024 was $7.67M, a 10.40% decline from fiscal 2023.
- CytomX Therapeutics, Inc. share-based payment arrangement, noncash expense for fiscal 2023 was $8.56M, a 34.80% decline from fiscal 2022.
- CytomX Therapeutics, Inc. share-based payment arrangement, noncash expense for fiscal 2022 was $13.13M, a 0.32% decline from fiscal 2021.
| Period end | Share-based Payment Arrangement, Noncash Expense | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $2.58M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $7.28M 10-Q · filed 2026-08-06 | $8.76M derived: sum of 3 quarters · filed 2026-08-06 | $10.15M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2026-03-31 | $4.71M 10-Q · filed 2026-05-07 | $6.18M derived: sum of 2 quarters · filed 2026-05-07 | $7.57M derived: sum of 3 quarters · filed 2026-05-07 | $9.00M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-12-31 | $1.48M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $2.86M derived: sum of 2 quarters · filed 2026-03-16 | $4.29M derived: sum of 3 quarters · filed 2026-08-06 | $6.30M 10-K · filed 2026-03-16 | |
| 2025-09-30 | $1.38M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $2.81M derived: sum of 2 quarters · filed 2026-08-06 | $4.82M 10-Q · filed 2025-11-06 | $6.71M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-06-30 | $1.43M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $3.44M 10-Q · filed 2026-08-06 | $5.32M derived: sum of 3 quarters · filed 2026-08-06 | $7.32M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-03-31 | $2.01M 10-Q · filed 2026-05-07 | $3.89M derived: sum of 2 quarters · filed 2026-05-07 | $5.89M derived: sum of 3 quarters · filed 2026-05-07 | $7.77M derived: sum of 4 quarters · filed 2026-05-07 | |
| 2024-12-31 | $1.88M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $3.88M derived: sum of 2 quarters · filed 2026-03-16 | $5.76M derived: sum of 3 quarters · filed 2026-03-16 | $7.67M 10-K · filed 2026-03-16 | |
| 2024-09-30 | $2.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $3.88M derived: sum of 2 quarters · filed 2025-11-06 | $5.78M 10-Q · filed 2025-11-06 | $8.34M derived: sum of 4 quarters · filed 2025-11-06 | |
| 2024-06-30 | $1.88M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $3.79M 10-Q · filed 2025-08-07 | $6.34M derived: sum of 3 quarters · filed 2025-08-07 | $7.57M derived: sum of 4 quarters · filed 2025-08-07 | |
| 2024-03-31 | $1.91M 10-Q · filed 2025-05-12 | $4.46M derived: sum of 2 quarters · filed 2025-05-12 | $5.68M derived: sum of 3 quarters · filed 2025-05-12 | $8.06M derived: sum of 4 quarters · filed 2025-05-12 | |
| 2023-12-31 | $2.55M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | $3.78M derived: sum of 2 quarters · filed 2025-03-06 | $6.15M derived: sum of 3 quarters · filed 2025-03-06 | $8.56M 10-K · filed 2025-03-06 | |
| 2023-09-30 | $1.23M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $3.60M derived: sum of 2 quarters · filed 2024-11-07 | $6.01M 10-Q · filed 2024-11-07 | $8.58M derived: sum of 4 quarters · filed 2024-11-07 | |
| 2023-06-30 | $2.37M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $4.78M 10-Q · filed 2024-08-08 | $7.35M derived: sum of 3 quarters · filed 2024-08-08 | $10.04M derived: sum of 4 quarters · filed 2024-08-08 | |
| 2023-03-31 | $2.41M 10-Q · filed 2024-05-08 | $4.98M derived: sum of 2 quarters · filed 2024-05-08 | $7.67M derived: sum of 3 quarters · filed 2024-05-08 | $12.16M derived: sum of 4 quarters · filed 2024-05-08 | |
| 2022-12-31 | $2.57M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-11 | $5.26M derived: sum of 2 quarters · filed 2024-03-11 | $9.76M derived: sum of 3 quarters · filed 2024-03-11 | $13.13M 10-K · filed 2024-03-11 | |
| 2022-09-30 | $2.69M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $7.18M derived: sum of 2 quarters · filed 2023-11-07 | $10.55M 10-Q · filed 2023-11-07 | $14.10M derived: sum of 4 quarters · filed 2023-11-07 | |
| 2022-07-13 | $200.00K 10-Q · filed 2022-11-08 | ||||
| 2022-06-30 | $4.49M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $7.86M 10-Q · filed 2023-08-08 | $11.40M derived: sum of 3 quarters · filed 2023-08-08 | $14.57M derived: sum of 4 quarters · filed 2023-08-08 | |
| 2022-03-31 | $3.37M 10-Q · filed 2023-05-09 | $6.91M derived: sum of 2 quarters · filed 2023-05-09 | $10.08M derived: sum of 3 quarters · filed 2023-05-09 | $13.50M derived: sum of 4 quarters · filed 2023-05-09 | |
| 2021-12-31 | $3.54M derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-03-27 | $6.71M derived: sum of 2 quarters · filed 2023-03-27 | $10.13M derived: sum of 3 quarters · filed 2023-03-27 | $13.17M 10-K/A · filed 2023-03-27 | |
| 2021-09-30 | $3.16M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $6.59M derived: sum of 2 quarters · filed 2022-11-08 | $9.62M 10-Q · filed 2022-11-08 | $13.04M derived: sum of 4 quarters · filed 2023-03-27 | |
| 2021-06-30 | $3.42M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $6.46M 10-Q · filed 2022-08-04 | $9.88M derived: sum of 3 quarters · filed 2023-03-27 | $13.72M derived: sum of 4 quarters · filed 2023-03-27 | |
| 2021-03-31 | $3.03M 10-Q · filed 2022-05-05 | $6.45M derived: sum of 2 quarters · filed 2023-03-27 | $10.29M derived: sum of 3 quarters · filed 2023-03-27 | $13.81M derived: sum of 4 quarters · filed 2023-03-27 | |
| 2020-12-31 | $3.42M derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-03-27 | $7.26M derived: sum of 2 quarters · filed 2023-03-27 | $10.77M derived: sum of 3 quarters · filed 2023-03-27 | $14.79M 10-K/A · filed 2023-03-27 | |
| 2020-09-30 | $3.84M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $7.35M derived: sum of 2 quarters · filed 2021-11-04 | $11.37M 10-Q · filed 2021-11-04 | $15.48M derived: sum of 4 quarters · filed 2023-03-27 | |
| 2020-06-30 | $3.51M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $7.53M 10-Q · filed 2021-08-05 | $11.64M derived: sum of 3 quarters · filed 2023-03-27 | $15.98M derived: sum of 4 quarters · filed 2023-03-27 | |
| 2020-03-31 | $4.01M 10-Q · filed 2021-05-06 | $8.12M derived: sum of 2 quarters · filed 2023-03-27 | $12.47M derived: sum of 3 quarters · filed 2023-03-27 | $17.92M derived: sum of 4 quarters · filed 2023-03-27 | |
| 2019-12-31 | $4.11M derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-03-27 | $8.45M derived: sum of 2 quarters · filed 2023-03-27 | $13.91M derived: sum of 3 quarters · filed 2023-03-27 | $19.10M 10-K/A · filed 2023-03-27 | |
| 2019-09-30 | $4.34M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $9.80M derived: sum of 2 quarters · filed 2020-11-05 | $14.99M 10-Q · filed 2020-11-05 | $19.61M derived: sum of 4 quarters · filed 2021-02-24 | |
| 2019-06-30 | $5.45M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $10.65M 10-Q · filed 2020-08-06 | $15.26M derived: sum of 3 quarters · filed 2021-02-24 | $19.68M derived: sum of 4 quarters · filed 2021-02-24 | |
| 2019-03-31 | $5.19M 10-Q · filed 2020-05-07 | $9.81M derived: sum of 2 quarters · filed 2021-02-24 | $14.22M derived: sum of 3 quarters · filed 2021-02-24 | $18.38M derived: sum of 4 quarters · filed 2021-02-24 | |
| 2018-12-31 | $4.62M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-24 | $9.03M derived: sum of 2 quarters · filed 2021-02-24 | $13.19M derived: sum of 3 quarters · filed 2021-02-24 | $16.88M 10-K · filed 2021-02-24 | |
| 2018-09-30 | $4.41M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | $8.57M derived: sum of 2 quarters · filed 2019-11-07 | $12.26M 10-Q · filed 2019-11-07 | $15.01M derived: sum of 4 quarters · filed 2020-02-27 | |
| 2018-06-30 | $4.16M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-07 | $7.85M 10-Q · filed 2019-08-07 | $10.60M derived: sum of 3 quarters · filed 2020-02-27 | $13.38M derived: sum of 4 quarters · filed 2020-02-27 | |
| 2018-03-31 | $3.69M 10-Q · filed 2019-05-09 | $6.44M derived: sum of 2 quarters · filed 2020-02-27 | $9.22M derived: sum of 3 quarters · filed 2020-02-27 | $12.23M derived: sum of 4 quarters · filed 2020-02-27 | |
| 2017-12-31 | $2.75M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | $5.53M derived: sum of 2 quarters · filed 2020-02-27 | $8.54M derived: sum of 3 quarters · filed 2020-02-27 | $11.29M 10-K · filed 2020-02-27 | |
| 2017-09-30 | $2.78M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-06 | $5.79M derived: sum of 2 quarters · filed 2018-11-06 | $8.54M 10-Q · filed 2018-11-06 | $11.16M derived: sum of 4 quarters · filed 2019-02-27 | |
| 2017-06-30 | $3.01M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-08 | $5.76M 10-Q · filed 2018-08-08 | $8.38M derived: sum of 3 quarters · filed 2019-02-27 | $11.10M derived: sum of 4 quarters · filed 2019-02-27 | |
| 2017-03-31 | $2.75M 10-Q · filed 2018-05-09 | $5.37M derived: sum of 2 quarters · filed 2019-02-27 | $8.09M derived: sum of 3 quarters · filed 2019-02-27 | $10.48M derived: sum of 4 quarters · filed 2019-02-27 | |
| 2016-12-31 | $2.62M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-27 | $5.34M derived: sum of 2 quarters · filed 2019-02-27 | $7.73M derived: sum of 3 quarters · filed 2019-02-27 | $10.10M 10-K · filed 2019-02-27 | |
| 2016-09-30 | $2.72M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | $5.11M derived: sum of 2 quarters · filed 2017-11-07 | $7.47M 10-Q · filed 2017-11-07 | $9.39M derived: sum of 4 quarters · filed 2018-03-07 | |
| 2016-06-30 | $2.39M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-07 | $4.75M 10-Q · filed 2017-08-07 | $6.67M derived: sum of 3 quarters · filed 2018-03-07 | $8.02M derived: sum of 4 quarters · filed 2018-03-07 | |
| 2016-03-31 | $2.36M 10-Q · filed 2017-05-05 | $4.28M derived: sum of 2 quarters · filed 2018-03-07 | $5.63M derived: sum of 3 quarters · filed 2018-03-07 | $6.17M derived: sum of 4 quarters · filed 2018-03-07 | |
| 2015-12-31 | $1.92M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-07 | $3.27M derived: sum of 2 quarters · filed 2018-03-07 | $3.81M derived: sum of 3 quarters · filed 2018-03-07 | $3.99M 10-K · filed 2018-03-07 | |
| 2015-09-30 | $1.34M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-03 | $1.89M derived: sum of 2 quarters · filed 2016-11-03 | $2.06M 10-Q · filed 2016-11-03 | $2.21M derived: sum of 4 quarters · filed 2017-03-02 | |
| 2015-06-30 | $546.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-03 | $721.00K 10-Q · filed 2016-08-03 | $865.00K derived: sum of 3 quarters · filed 2017-03-02 | ||
| 2015-03-31 | $175.00K 10-Q · filed 2016-05-06 | $319.00K derived: sum of 2 quarters · filed 2017-03-02 | |||
| 2014-12-31 | $144.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-02 | $553.00K 10-K · filed 2017-03-02 | |||
| 2014-09-30 | $409.00K 10-Q · filed 2015-11-23 | ||||
| 2013-12-31 | $343.00K 10-K · filed 2016-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |